PIK3CA, which encodes the p100α catalytic subunit of PI3K [29], is the target of several PI3K inhibitors used to treat breast cancer (alpelisib), follicular lymphoma (copanlisib), and chronic lymphocytic leukemia (idelalisib). This evidence concerns the gene PIK3CA and breast carcinoma.